Status:
COMPLETED
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Lead Sponsor:
Actelion
Conditions:
Psoriasis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
Eligibility Criteria
Inclusion
- Adult males and females aged 18 to 60 years (inclusive) with moderate to severe chronic plaque psoriasis who require systemic treatment.
Exclusion
- Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis.
- Systemic or topical treatments for psoriasis other than emollients. Ongoing bacterial, viral or fungal infections.
- History or presence of malignancy.
- Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.
Key Trial Info
Start Date :
October 31 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2012
Estimated Enrollment :
326 Patients enrolled
Trial Details
Trial ID
NCT01208090
Start Date
October 31 2010
End Date
November 30 2012
Last Update
March 30 2025
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Investigative Site 1006
Feldkirch, Austria, 6807
2
Clinical Investigative Site 1002
Graz, Austria, 8036
3
Clinical Investigative Site 1004
Sankt Pölten, Austria, 3100
4
Clinical Investigative Site 1007
Vienna, Austria, 1130